Citation Impact
Citing Papers
Probing mucin-type O-linked glycosylation in living animals
2006 StandoutNobel
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
2009
Membrane-tethered mucin-like polypeptides sterically inhibit binding and slow fusion kinetics of influenza A virus
2020 StandoutNobel
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
2015
Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification
2012
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
Cancer statistics, 2022
2022 Standout
Membrane curvature regulates the spatial distribution of bulky glycoproteins
2022 StandoutNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution
2024 StandoutNobel
Cancer Statistics, 2021
2021 Standout
Mucins in cancer: function, prognosis and therapy
2009
Tipin-Replication Protein A Interaction Mediates Chk1 Phosphorylation by ATR in Response to Genotoxic Stress
2010 StandoutNobel
Mechanisms of Thrombus Formation
2008 Standout
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
2009
Thyroid cancer
2016 Standout
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
2007
Host tissue determinants of tumour immunity
2019
The cancer glycocalyx mechanically primes integrin-mediated growth and survival
2014 StandoutNatureNobel
The biology and management of non-small cell lung cancer
2018 StandoutNature
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
2006
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Imaging the Glycosylation State of Cell Surface Glycoproteins by Two‐Photon Fluorescence Lifetime Imaging Microscopy
2013 StandoutNobel
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
2014
The DNA Damage Response Kinases DNA-dependent Protein Kinase (DNA-PK) and Ataxia Telangiectasia Mutated (ATM) Are Stimulated by Bulky Adduct-containing DNA
2011 StandoutNobel
A Selenium Analogue of Firefly D ‐Luciferin with Red‐Shifted Bioluminescence Emission
2012 StandoutNobel
Lung Cancer
2008 Standout
The MET axis as a therapeutic target
2009
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
2010 Standout
The Cancer Genome Atlas Pan-Cancer analysis project
2013 Standout
Cell surface-associated mucins in signal transduction
2006
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Lung cancer: current therapies and new targeted treatments
2016 Standout
Glycans in cancer and inflammation — potential for therapeutics and diagnostics
2005 StandoutNobel
Pharmacology of Airway Goblet Cell Mucin Release
2003
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
2013
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
2009
Revealing the human mucinome
2022 StandoutNobel
Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold
2011
The F Box Protein Fbx6 Regulates Chk1 Stability and Cellular Sensitivity to Replication Stress
2009
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
2010
Chemical Approaches To Perturb, Profile, and Perceive Glycans
2009 StandoutNobel
Targeting DNA repair mechanisms in cancer
2012
How Chemoproteomics Can Enable Drug Discovery and Development
2012
Airway Mucus Function and Dysfunction
2010 Standout
Molecular signaling in the regulation of mucins
2007
Glycocalyx Engineering with a Recycling Glycopolymer that Increases Cell Survival In Vivo
2015 StandoutNobel
The biology and treatment of EML4-ALK non-small cell lung cancer
2010
Mucins in cancer: protection and control of the cell surface
2003
The sweet and sour of cancer: glycans as novel therapeutic targets
2005
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Cell cycle kinases as therapeutic targets for cancer
2009
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer
2017
Advances in Mucous Cell Metaplasia
2009
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
2010
Hierarchical Assembly of Model Cell Surfaces: Synthesis of Mucin Mimetic Polymers and Their Display on Supported Bilayers
2007 StandoutNobel
Control of the Molecular Orientation of Membrane-Anchored Biomimetic Glycopolymers
2009 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer
2014
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
2014
Density Variant Glycan Microarray for Evaluating Cross-Linking of Mucin-like Glycoconjugates by Lectins
2012 StandoutNobel
Structure and Function of the Cell Surface (Tethered) Mucins
2007
MET As a Possible Target for Non–Small-Cell Lung Cancer
2013
Lysosomal cathepsin D mediates endogenous mucin glycodomain catabolism in mammals
2022 StandoutNobel
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
Trousseau's syndrome: multiple definitions and multiple mechanisms
2007
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
2015
In Vivo Bioluminescent Imaging (BLI): Noninvasive Visualization and Interrogation of Biological Processes in Living Animals
2010
Inhibitors of the anaplastic lymphoma kinase
2012
Chemically tunable mucin chimeras assembled on living cells
2015 StandoutNobel
A Chemical Reporter Strategy to Probe Glycoprotein Fucosylation
2006 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Imaging the glycome
2008 StandoutNobel
Fit-for-Purpose Development of the Enabling Route to Crizotinib (PF-02341066)
2011
Interfacing Carbon Nanotubes with Living Cells
2006 StandoutNobel
Anaplastic lymphoma kinase: signalling in development and disease
2009
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations
2011
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
2014
Noncovalent Cell Surface Engineering: Incorporation of Bioactive Synthetic Glycopolymers into Cellular Membranes
2008 StandoutNobel
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras
2008
Corneal surface glycosylation is modulated by IL‐1R and Pseudomonas aeruginosa challenge but is insufficient for inhibiting bacterial binding
2017 StandoutNobel
Chemical Glycoproteomics
2016 StandoutNobel
Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
2009
Works of Maria E. Arango being referenced
An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms
2007
PF-00477736 Mediates Checkpoint Kinase 1 Signaling Pathway and Potentiates Docetaxel-Induced Efficacy in Xenografts
2009
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1
2008
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
2007
AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity
2005
Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor
2001
Rat Muc4 (sialomucin complex) reduces binding of anti‐ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance
2002
An ErbB2-Muc4 complex in rat ocular surface epithelia
2002
Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27kip, but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways
2002
Production and localization of Muc4/sialomucin complex and its receptor tyrosine kinase ErbB2 in the rat lacrimal gland.
2001
Muc4/sialomucin complex, the intramembrane Er6B2 ligand, in cancer and epithelia: To protect and to survive
2002
Advancing Bioluminescence Imaging Technology for the Evaluation of Anticancer Agents in the MDA-MB-435-HAL-Luc Mammary Fat Pad and Subrenal Capsule Tumor Models
2008
Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysis
2002